

Decrease Colorectal Cancer Death (DeCoDe)

 consortiapedia.fastercures.org/consortia/decode/

Research Areas



Biomarker Research

Diagnostic, Genomic Biomarker

At a Glance

- Status: **Completed Consortium**
- Year Launched: **2008**
- Initiating Organization: **Center for Translational Molecular Medicine**
- Initiator Type: **Government**
- Location: **Europe**

Abstract

There is a global consensus among colorectal cancer (CRC) experts that the most promising strategies to relieve these burdens and decrease CRC rates are early detection and staging strategies and personalized therapies based upon individual tumor characteristics. The DeCoDe project aims to address these gaps in the CRC care cycle by translating recent biological and technological advances into clinical applications and practice. For molecular early diagnosis and pre-cancer detection, it will develop and validate biomarkers in stool deoxyribonucleic acid (DNA) and serum/tumor samples to develop genomic and proteomics tests as well as molecular magnetic resonance imaging (MRI)-based virtual colonoscopy. Molecular stool and serum tests will be validated in a series of up to 5,000 individuals (both population screening and clinical) undergoing the gold standard test, colonoscopy.

Mission

To achieve early molecular diagnosis and pre-cancer detection, the DeCoDe project aims to identify new methylated DNA and protein-based CRC biomarkers and validate them in stool and serum samples of large cohorts, as well as to develop molecular MRI-based virtual colonoscopy. Clinical needs in patients with primary CRC will be addressed by developing image-guided surgery and DNA

copy number and methylation-based biomarkers for predicting risk of recurrence and response to drug therapy. In patients with metastatic CRC, DNA copy number and methylation-based biomarkers for predicting response to anti-cancer drug therapy are being developed. In addition, novel biomarkers will be further developed into new positron emission tomography (PET) tracers.

Consortium History

Sept. 1, 2008: Start date

Aug. 31, 2013: End date

Financing

The project budget is €18.6 million.

Funding, via the Center for Translational Molecular Medicine, is provided by the Dutch government, industry, and academia. The research is focused firmly on the translational aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.

Links/Social Media Feed

Homepage

<http://www.ctmm.nl/en/projecten/kanker/decode>

Sponsors & Partners

Gerrit A. Meijer

Principal Investigator

DeCoDe/TraIT/CRCbioscreen

Eric Caldenhoven

Program Manager Oncology

phone: +31 (0)40 800 23 05

fax: eric.caldenhoven@ctmm.nl

Academic Medical Center Amsterdam (AMC)

Cyclotron VU

Dionex

Erasmus MC

Erasmus University Rotterdam (EUR)

Leiden University Medical Center

Maastricht UMC

MDxHealth

MRC Holland

NIPED

Percuros

Philips

ServiceXS

VU University Medical Center Amsterdam

Updated: **04/14/2016**